Ventripoint Diagnostics Ltd.

VPT

CA92281P2008

Advanced Medical Equipment & Technology

Market Closed - Toronto S.E. Other stock markets 15:01:50 16/07/2024 BST			5-day change	1st Jan Change
0.21 ^CAD	0.00%		0.00%	-28.81%

06-13	Ventripoint Diagnostics Ltd. Appoints Matt Dobson as Marketing Director	CI
05-31	Ventripoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

VentriPoint Diagnostics Ltd. Announces Appointment of Andriy Shmatukha as Software Developer

February 07, 2018 at 03:33 pm

VentriPoint Diagnostics Ltd. announced that Dr. Andriy Shmatukha has joined the Ventripoint team as software developer to advance the Ventripoint products and technology.

Latest news about Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics Ltd. Appoints Matt Dobson as Marketing Director	06-13	CI
Ventripoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-31	CI
Ventripoint Diagnostics Ltd. Submits Next Generation of Software, VMS+4.0, to the U.S. Food and Drug Administration	05-06	CI
Duke University Health Center Purchases Ventripoint's AI Heart-Scan Technology	05-01	CI
Ventripoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
VentriPoint Diagnostics Ltd. announced that it expects to receive CAD 3 million in funding	04-10	CI
Ventripoint Diagnostics Ltd. Releases Significant Upgrade to the Design and Function of Its Whole-Heart Analysis System (VMS+3.2)	03-04	CI
Ventripoint Diagnostics Ltd. Showcases A.I. Powered Heart-Scanning Technology at International Cardiology Conferences	02-20	CI
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as Interim CEO	02-05	CI
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President	02-05	CI
The Paediatric Heart Centre At the Medical University of Vienna Has Chosen to Adopt the Vms+ as Its Cardiac Diagnostic Tool	02-01	CI
VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board	01-20	CI
VentriPoint Diagnostics Ltd. Enters into A Global Distribution and Marketing Agreement with Ascend Cardiovascular	12-12	CI
VentriPoint Diagnostics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
VentriPoint Diagnostics Ltd. Announces Executive Changes	03/10/23	CI
VentriPoint Diagnostics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23	CI
Ventripoint Welcomes Evelina London Children's Hospital as Newest Vms+ User	22/08/23	CI
Ventripoint Diagnostics Ltd. Announces That Ventripoint and Ascend Cardiovascular, Llc Have Developed A New Integrated Product	18/08/23	CI
Ventripoint Diagnostics Ltd. Announces Collaboration with Ascend Cardiovascular	10/08/23	CI
VentriPoint Diagnostics Ltd. Announces Purchase of VMS+ by Medical Center University of Freiburg	18/07/23	CI
VentriPoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23	CI
VentriPoint Diagnostics Ltd. Auditor Raises 'Going Concern' Doubt	30/04/23	CI
VentriPoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	30/04/23	CI
Ventripoint Diagnostics Ltd. Announces Appointment of Alvira Macanovic as President	03/01/23	CI
Ventripoint Diagnostics Ltd Announces Appointment of Alvira Macanovic as CEO	03/01/23	CI

Chart Ventripoint Diagnostics Ltd.

Duration

Period

More charts

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Companyâs Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heartâs structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The systemâs proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).

Sector

Advanced Medical Equipment & Technology

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
VENTRIPOINT DIAGNOSTICS LTD.	-28.81%	24.16M
THERMO FISHER SCIENTIFIC	+4.64%	208B
DANAHER CORPORATION	+8.99%	182B
INTUITIVE SURGICAL, INC.	+29.83%	155B
BOSTON SCIENTIFIC CORPORATION	+35.17%	115B
SIEMENS HEALTHINEERS AG	+2.55%	66.52B
EDWARDS LIFESCIENCES CORPORATION	+15.06%	53.93B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-6.47%	46.26B
AGILENT TECHNOLOGIES, INC.	-2.14%	38.22B
GE HEALTHCARE TECHNOLOGIES INC.	+6.88%	36.6B